Antisense News and Research

RSS
Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.
iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics reports financial results for first quarter 2015

Bayer to further develop ISIS-FXIRx antisense investigational drug for thrombosis prevention

Bayer to further develop ISIS-FXIRx antisense investigational drug for thrombosis prevention

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Study explores innovative approach to identifying successful treatment for HER2+ breast cancer

Researchers provide new clues, mechanisms to understand functions of 'rebel' DNA in cancer

Researchers provide new clues, mechanisms to understand functions of 'rebel' DNA in cancer

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Researchers reveal how malaria parasite deploys genetic trickery to escape immune system attack

Researchers reveal how malaria parasite deploys genetic trickery to escape immune system attack

Beckman Coulter Genomics Introduces a Scalable RNA-seq service line for processing intact and degraded RNA samples

Beckman Coulter Genomics Introduces a Scalable RNA-seq service line for processing intact and degraded RNA samples

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Experimental Ebola virus medication shows promise in monkeys

Experimental Ebola virus medication shows promise in monkeys

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Vanderbilt researchers find link between the biological clock and Angelman syndrome

Vanderbilt researchers find link between the biological clock and Angelman syndrome

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Isis receives $10 million from Biogen Idec to begin IND-supporting studies of ISIS-BIIB4 Rx

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Study demonstrates therapeutic potential of new class of synthetic oligonucleotides for DMD treatment

Bern researchers develop active substance for treating Duchenne muscular dystrophy

Bern researchers develop active substance for treating Duchenne muscular dystrophy

Scientists create largest ever catalogue of biological chimeras

Scientists create largest ever catalogue of biological chimeras

Researchers gain new insight into how motor neurons in the brain die during ALS

Researchers gain new insight into how motor neurons in the brain die during ALS

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

Isis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.